MED-X, INC. Maximum: 25,000,000 Shares of Common Stock $0.001 par value per share SELLING AGENCY AGREEMENT July__, 2019Selling Agency Agreement • July 15th, 2019 • Med-X, Inc. • Pharmaceutical preparations • California
Med-X, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained in this Selling Agency Agreement (this “Agreement”), to issue and sell up to a maximum of 12,500,000 shares of its common stock, $0.001 par value per share (the “Common Stock”), to investors (collectively, the “Investors”) in a public offering (the “Offering”) pursuant to Regulation A through NMS Capital Advisors, LLC, as Selling Agent (collectively, the “Selling Agent”), acting on a best efforts basis only, in connection with such sales. The shares of Common Stock to be sold in this offering are referred to herein as the “Shares.” The Shares are more fully described in the Offering Statement (as hereinafter defined).
Amendment No. 1 to Engagement AgreementEngagement Agreement • July 15th, 2019 • Med-X, Inc. • Pharmaceutical preparations • California
Reference is made to the Engagement Agreement, dated April 29, 2019, (the “Engagement Agreement”), by and between NMS Capital Advisors, LLC (“NMS”) and Med-X, Inc. (the “Company”). All capitalized terms used in this Amendment No. 1 to the Engagement Agreement (this “Amendment”) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Engagement Agreement. NMS and the Company agree as follows:
